Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine how people with weakened immune systems
and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous
squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is
approved for sale in United States by the U.S. Food and Drug Administration (FDA).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute